600211.SH
西藏药业
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 38.16
−2.13%Year over year
Reported trailing growth
- Revenue
- +6.3%
- EBITDA
- —
- EBIT
- -5.2%
- EPS
- -4.0%
- Free cash flow
- +28.6%
- Operating cash flow
- +24.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.3%
- EBITDA
- +28.1%
- EBIT
- +31.0%
- Net income
- +36.4%
- EPS
- +25.0%
- Free cash flow
- +10.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026